US10085826B2 - Absorbable/biodegradable composite yarn constructs and applications thereof - Google Patents
Absorbable/biodegradable composite yarn constructs and applications thereof Download PDFInfo
- Publication number
- US10085826B2 US10085826B2 US14/795,922 US201514795922A US10085826B2 US 10085826 B2 US10085826 B2 US 10085826B2 US 201514795922 A US201514795922 A US 201514795922A US 10085826 B2 US10085826 B2 US 10085826B2
- Authority
- US
- United States
- Prior art keywords
- yarn
- mesh
- biodegradable
- knitted mesh
- yarn component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0063—Implantable repair or support meshes, e.g. hernia meshes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
- A61L17/105—Polyesters not covered by A61L17/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
- A61L17/12—Homopolymers or copolymers of glycolic acid or lactic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/14—Post-treatment to improve physical properties
- A61L17/145—Coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/129—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing macromolecular fillers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04B—KNITTING
- D04B21/00—Warp knitting processes for the production of fabrics or articles not dependent on the use of particular machines; Fabrics or articles defined by such processes
- D04B21/10—Open-work fabrics
- D04B21/12—Open-work fabrics characterised by thread material
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04C—BRAIDING OR MANUFACTURE OF LACE, INCLUDING BOBBIN-NET OR CARBONISED LACE; BRAIDING MACHINES; BRAID; LACE
- D04C1/00—Braid or lace, e.g. pillow-lace; Processes for the manufacture thereof
- D04C1/06—Braid or lace serving particular purposes
- D04C1/12—Cords, lines, or tows
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0063—Implantable repair or support meshes, e.g. hernia meshes
- A61F2002/0068—Implantable repair or support meshes, e.g. hernia meshes having a special mesh pattern
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/003—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2401/00—Physical properties
- D10B2401/12—Physical properties biodegradable
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2509/00—Medical; Hygiene
- D10B2509/04—Sutures
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2509/00—Medical; Hygiene
- D10B2509/08—Hernia repair mesh
Definitions
- This invention relates to composite warp knitted and braided constructs, each comprising two types of yarns having significantly different absorption/biodegradation and strength retention profiles to produce warp-knitted meshes and braided sutures exhibiting bimodular changes in their properties when used as surgical implants.
- Blending of non-absorbable fibers having distinctly different individual physicochemical properties is a well-established practice in the textile industry and is directed toward achieving unique properties based on the constituent fibers in such blends.
- the most commonly acknowledged examples of these blends include combinations of (1) wool staple yarn and polyethylene terephthalate (PET) continuous multifilament yarn to produce textile fabrics which benefit from the insulating quality of wool and high tensile strength of the polyester; (2) cotton staple yarn and PET continuous multifilament yarn to produce water-absorbing, comfortable (due to cotton), strong (due to PET) fabrics; (3) nylon continuous multifilament yarn and cotton staple yarn to achieve strength and hydrophilicity; and (4) cotton staple yarn and polyurethane continuous monofilament yarn to yield water-absorbing, comfortable elastic fabrics.
- PET polyethylene terephthalate
- the present invention is directed to warp knitted composite meshes and braided composite sutures comprising slow-absorbable/biodegradable and fast-absorbable/biodegradable components, specially sized and constructed to produce surgical devices having unique properties.
- One major aspect of this invention is directed to a warp-knitted composite mesh with a minimum area density of 50 g/m 2 , which includes (a) a slow absorbing/biodegradable multifilament yarn component having individual filament diameter of less than 20 micron; and (b) a fast-absorbing multifilament yarn component having individual filament diameter exceeding 20 micron, wherein the slow-absorbing/biodegradable multifilament component is a segmented copolymer made of molecular chains comprising at least 80 percent of l-lactide-based sequences and the fast-absorbing multifilament component is a segmented polyaxial copolymer made of molecular chains comprising at least 70 percent of glycolide-derived sequences, and wherein the slow-absorbing multifilament component is knitted in a 2-bar sand-fly net pattern and the fast-absorbing multifilament component is knitted in a standard 2-bar marquisette pattern, with all guide bars threaded 1-in and 1-out, using a warp
- the slow-absorbing multifilament component is knitted in 2-bar full tricot pattern and the fast-absorbing multifilament component yarn is knitted in a standard 2-bar marquisette pattern with all guide bars threaded 1-in and 1-out, using a warp knitting machine.
- a clinically important aspect of this invention is the provision of a composite mesh having an area weight of about 130 g/m 2 and exhibiting a maximum burst force of at least 250 N and a maximum elongation of less than 10 percent under a 16 N force per cm of mesh width, and when incubated in buffered solution at pH 7.2 and 50° C. for about 2 weeks retains more than 20 percent of its maximum burst force and undergoes at least 12 percent elongation under a force of 16 N per cm of mesh width.
- the slow-absorbing/biodegradable multifilament yarn component of the mesh comprises a poly-3-hydroxyalkanoate made of molecular chains consisting of at least 50 percent of 3-hydroxybutyric acid-derived sequences.
- This invention also deals with a warp-knitted composite mesh with a minimum area density of 50 g/m 2 , comprising (a) a slow absorbing/biodegradable multifilament yarn component having individual filament diameter of less than 20 micron; and (b) a fast-absorbing multifilament yarn component having individual filament diameter exceeding 20 micron, wherein said mesh is coated with an absorbable polymer at a coating add-on of at least 0.1 percent based on the uncoated mesh weight.
- the coating comprises a polyaxial copolyester made of molecular chains comprising about 95/5 ⁇ -caprolactone-/glycolide-derived sequences, wherein the coating contains at least 1 bioactive agent selected from those groups known for their antineoplastic, anti-inflammatory, antimicrobial, anesthetic and cell growth-promoting activities.
- Another major aspect of this invention deals with a braided composite suture comprising (a) a slow-absorbing/biodegradable multifilament yarn component having individual filament diameter of less than 20 micron, and capable of retaining at least 20 percent of its initial breaking strength when tested individually as a braid and incubated in a phosphate buffer at pH 7.2 and 50° C. for about 2 weeks; and (b) a fast-absorbing/biodegradable multifilament yarn component capable of retaining at least 20 percent of its initial breaking strength when tested individually as a braid and incubated in a phosphate buffer at pH 7.2 and 50° C. for about 1 day.
- the slow-absorbing/biodegradable and fast-absorbing/biodegradable multifilament components constitute the core and sheath of the braid, respectively.
- the slow-absorbing/biodegradable and fast-absorbing/biodegradable multifilament components constitute the sheath and core of the braid, respectively.
- the slow-absorbing/biodegradable multifilament component comprises a segmented copolymer made of the molecular chains consisting of at least 80 percent of l-lactide-derived sequences and the fast-absorbing/biodegradable multifilament component comprises a segmented polyaxial copolymer made of molecular chains consisting of at least 70 percent of glycolide-derived sequences.
- the slow absorbable/biodegradable multifilament component comprises silk, or a poly-3-hydroxyalkanoate made of a molecular chain consisting of at least 50 percent of 3-hydroxybutyric acid-derived sequences.
- the coating comprises a polyaxial copolyester made of molecular chains comprising about 95/5 ⁇ -caprolactone-/glycolide-derived sequences, wherein the coating contains at least one bioactive agent selected from those groups known for their antineoplastic, anti-inflammatory, antimicrobial, anesthetic and cell growth-promoting activities.
- an acute inflammation prevails at the implant site. This is manifested as redness, heat, swelling and pain. After about day three, any persistent local inflammatory response to the implant subsides.
- the acute inflammation persists for less than a week and the development of a fibrous connective tissue around the implant progresses for about a month, leading to a generally static, fibrous capsule.
- a long-term separation of the non-absorbable implant from surrounding tissues by the capsule can lead to complications. Depending on the type of implant site, these complications may (1) increase the risk of infection and (2) interfere with the integration of the implant components with surrounding tissue leading to mechanical instability, as in the case of hernial meshes.
- the inflammation can be restimulated, incrementally, during the implant residence time period at the site, a feature which can be most desirable in certain applications.
- These include surgical meshes used in hernial repair, where an incremental restimulation of inflammation can result in controlled and persistent collagen deposition and mechanical integration with the fibrous components of the mesh leading to critically needed mechanical stability. Obviously, one should not expect this to terminate after the first three or four weeks following implantation leading to catastrophic mechanical failure of the mesh.
- the incremental restimulation of inflammation and controlled collagen deposition can be achieved through (1) movement of the mesh components and/or at the mesh-tissue interface; (2) providing continually increased porosity in the mesh to permit progressively increasing facile fibroblast migration; and (3) having structurally stable mesh construction that resists tear and unraveling under dynamic mechanical stresses.
- the mesh components should be designed to (1) exhibit at least two absorption/strength retention profiles, one that prevails during the first two to four weeks and a second which will be responsible for continued restimulation beyond four weeks; (2) display sufficient mechanical strength and stiffness in the first three to four weeks during which collagen is deposited and the mechanical load at the site commences to be shared between the mesh and surrounding tissue without experiencing premature deformation; (3) accommodate the biomechanical events associated with wound healing and tissue shrinkage, as well as incremental dynamic stresses due to regular motions of active patients, through an incremental increase in the engineering compliance of the mesh; and (4) have a carefully warp-knitted construction that accommodates mechanical changes at the implant site while resisting tearing and breaking/unraveling at the tissue-mesh interface and/or within the mesh construct itself.
- the present invention addresses the requirements set forth for an optimal mesh. Similarly, it addresses the requirements of an optimum suture that is expected to provide an effective ligation for three to four weeks as well as up to a few months following implantation, as would be required for wound repairs of compromised and slow-healing tissues.
- a key general aspect of this invention is directed to a warp-knitted composite mesh with minimum density of 50 g/m 2 to ensure having adequate mass and strength to allow anchoring to the natural tissue, using a suture and/or absorbable adhesive, without tearing, unraveling, and/or breaking immediately after placement and during the first few weeks of functional performance. This is to prevent mechanical failure at the tissue-mesh interface or within the mesh components.
- an absorbable suture of choice will be expected to maintain a strength retention profile that parallels that of a long-lasting component of the composite mesh.
- the composite mesh is expected to comprise (1) a slow-absorbing/biodegradable, multifilament yarn component having individual filament diameter of less than 20 micron and preferably less than 15 micron as the main, relatively more flexible matrix of the mesh, which retains a measurable breaking strength for at least six weeks and preferably for more than eight weeks; (2) a fast-absorbing/biodegradable, multifilament yarn component having individual filament diameter of more than 20 micron and preferably exceeding 25 micron, as the minor, relatively less flexible component of the mesh that will be responsible for providing adequate initial rigidity of the mesh, and facile anchoring to the surrounding tissues, while exhibiting a brief breaking strength profile of about two to four weeks—this is to allow the slow-absorbing flexible matrix to become progressively more extensible at about two to four weeks following implantation; and (3) a slow- and fast-absorbing multifilament components in specially designed warp-knitted construction to ensure their mechanical interdependence in terms of load-bearing contributions and ability to anchor to the surrounding tissue using an absorbable tissue adhesive, absorbable suture,
- An alternative composite mesh construction entails knitting the slow-absorbing component using a 2-bar full tricot pattern and the fast-absorbing component using a standard 2-bar marquisette pattern, with all guide bars threaded 1-in and 1-out in 18 gauge.
- the warp construction can be achieved using other patterns.
- a lubricant coating is applied to the mesh at a level of 0.1 to 10 percent based on the mesh uncoated weight.
- the absorbable coating can also be used as a carrier for the controlled release of one or more bioactive agents belonging to one or more group of drugs known for their antimicrobial, anti-adhesion, and growth-promoting agents.
- the ideal coating system can be a crystalline, easy-to-apply, lubricious polymeric system that provides surface lubricity and its composition can be controlled to assist in modulating the absorption/biodegradation profile of the fast-absorbing component at least in the first two weeks following implantation.
- slow- and fast-absorbable/biodegradable components of the composite are, so far, described as multifilament yarns, which are warped independently
- other alternative approaches can be used entailing (1) plying the fast- with the slow-absorbable/biodegradable yarns prior to warping; (2) using one or more additional yarns with a moderate or fast absorption/biodegradation profile; (3) using the fast-absorbing component as a single or two-ply monofilament; (4) using a yarn component based on an elastomeric polymer—this can be in the form of a fast-, moderate- or faster-absorbing monofilament, 2-ply monofilament or multifilament.
- elastomeric components is expected to accommodate any transient change in stress at the application site at the initial period of implantation when inflammation-induced swelling is encountered.
- enzymatically biodegradable, multifilament yarn can be used as the slow-biodegrading component.
- Such yarns include those based on silk fibroin, poly-4-hydroxyalkanoate, casein, chitosan, soy protein, and similar naturally derived materials with or without chemical modification to modulate their biodegradation and breaking strength retention profiles.
- Another key general aspect of this invention is directed to a braided suture comprising at least two absorbable/biodegradable monofilament and/or multifilament yarn components having a range of absorption/biodegradation and breaking strength retention profiles.
- the rationale for invoking such a diversity in the components constituting the composite braid is practically similar to that noted above for composite mesh, with the exception of the fact that in constructing the braid, there is an additional degree of freedom, namely, having a core and sheath as the basic structural components of the braid.
- the braid construction may entail (1) using variable ratios of the core-to-sheath without encountering core popping; (2) having slow-absorbable/biodegradable, multifilament yarn as the core or sheath with the balance of braid consisting of a fast-absorbable/biodegradable multifilament yarn; (3) using elastomeric monofilament, plied monofilament or multifilament yarn as part of the braid construct and preferably in the core at variable levels to impart a controlled level of elasticity—this is to accommodate site swelling during the first few days following suture implantation.
- the composite suture can be coated to (1) improve its tie-down and handling properties; (2) possibly prolong the breaking strength retention profile; and (3) function as an absorbable carrier for the controlled release of one or more bioagent selected from the groups known for their antimicrobial, anti-adhesion, antithrombogenic, antiproliferative, antineoplastic, anti-inflammatory, and cell growth-promoting activities.
- the coating can also be used to allow the controlled and timely delivery of anesthetic agents to mediate pains following surgery.
- a useful feature of using a coating with an antineoplastic agent allows the use of the composite suture in cancer patients to minimize the likelihood of metastasis.
- Another useful feature is the use of the composite suture in anchoring synthetic vascular graft and perivascular wrap where (1) having two or more absorption/biodegradation profiles can allow accommodating physicomechanical changes at the suture line due to prevailing biological events; and (2) using antithrombogenic and/or antiproliferative agents can be beneficial in maintaining the long-term patency of the graft.
- a clinically important aspect of this invention deals with bioactive meshes comprising a coating containing an antineoplastic, anti-inflammatory, and/or antiproliferative agent that allows the use of the composite mesh as vascular wrap in the management of vascular embolism.
- the extruded multifilament yarn was further oriented using a one-stage drawing over a heated Godet at about 100-120° C. prior to its use for knitted mesh construction. Typical properties of Yarn I are shown below.
- the fast-absorbing/biodegradable component of the composite mesh a polyaxial, segmented glycolide copolymer (P2), made by ring-opening polymerization of a combination of an 88/7/5 (weight) glycolide/trimethylene carbonate/l-lactide [using the general polymerization method described in U.S. Pat. No. 7,129,319 (2006)] was melt-spun using a 10-hole die and oriented by in-line drawing. Typical properties of Yarn II and the form used in knitting are shown below.
- P2 polyaxial, segmented glycolide copolymer
- Compositions consisting of Yarns I and II which possess different degradation profiles (one relatively fast degrading and one slow degrading) were constructed using various knitting patterns to construct the desired warp-knitted meshes. Knit constructions were produced using a two-step process of warping yarn onto beams and constructing meshes using a typical Raschel or tricot knitting machine. Various knitting patterns and weight ratios of I to II can and were varied to modulate mechanical properties of the specific mesh. Knit constructions can be made from multifilament yarn, monofilament yarn, or combinations thereof. Knit mesh was heat set or annealed at 120° C. for 1 hour while under constant strain in the wale and course directions. Coating can be applied following annealing to modify the in vivo and/or in vitro characteristics.
- the knitting process utilized two warped beams of Yarn I, threaded on bars 1 and 2, and two warped beams of Yarn II threaded on bars 3 and 4.
- the knitting machine was equipped with 18-gauge needles.
- Yarn II was knitted in a 2-bar marquisette pattern and Yarn I was knitted in a 2-bar sand-fly net pattern with all guide bars for each pattern threaded 1-in and 1-out in 18 gauge.
- the knitting process utilized two warped beams of Yarn I threaded on bars 1 and 2 and two warped beams of Yarn II, threaded on bars 3 and 4.
- the knitting machine was equipped with 18-gauge needles.
- Yarn II was knitted in a 2-bar marquisette pattern and Yarn I was knitted in a 2-bar full tricot pattern with all guide bars for each pattern threaded 1-in and 1-out in 18 gauge.
- the extension at 71 N is used to determine the 16 N/cm elongation.
- the mesh has a 44.45 mm diameter and is all in one plane.
- the ball pushes the mesh downward and creates a cone like shape with the radius of the ball as the tip.
- CAD and curve fitting software a mathematical expression which relates the linear travel of the ball to the change in length of a line that passes under the center of the ball and up to the original 44.45 mm diameter (radial distension) was developed. From this information the percent elongation was determined
- Pattern B Warp Knit Composite Mesh Following Accelerated In Vitro Conditioning (12 pH, 50° C., 10 days) Elongation Elongation Sample Max. Burst at Max at 71 N Elongation at Description Force (N) Force (mm) Force (mm) 16 N/cm (%) Pattern B 240 19.4 13.2 18.5
- the same polymer precursor, P2, described in Example 1 was used in preparing multifilament Yarn III.
- the polymer was melt-spun using a 20-hole die to produce multifilament Yarn III, which was further oriented using one-stage drawing over a heated Godet at about 100-120° C., prior to its use in braid construction.
- Braid SM1-1 was prepared using a 4-carrier core of Yarn I as single ply and 8-carrier Yarn III as 3-ply.
- the braid was hot-stretched to about 5-10 percent of its initial length using heated air at about 90° C. to tighten the braid construction.
- the strained braid was then annealed at 110° C. for 1 hour to yield a braided suture having about 110 ppi and a diameter of about 0.35 mm.
- Braid SM1-2 was prepared using a 6-carrier core of Yarn III as single ply and 16-carrier sheath of Yarn I as single ply.
- the braid was hot stretched and annealed as described in Example 8 to yield a braided suture having about 50 ppi and a diameter of about 0.36.
- the braids were sterilized with ethylene oxides and tested for their (1) initial physical properties; (2) accelerated in vitro breaking strength retention profile at pH 7.2 and 50° C.; and (3) in vivo breaking strength retention using a subcutaneous rat model.
- the results of the in vitro and in vivo evaluation are summarized in Table VIII.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Textile Engineering (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Manufacturing & Machinery (AREA)
- Composite Materials (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Knitting Of Fabric (AREA)
Abstract
Absorbable composite medical devices such as surgical meshes and braided sutures, which display two or more absorption/biodegradation and breaking strength retention profiles and exhibit unique properties in different clinical settings, are made using combinations of at least two types of yarns having distinctly different physicochemical and biological properties and incorporate in the subject construct special designs to provide a range of unique properties as clinically useful implants.
Description
The present application is a continuation of U.S. application Ser. No. 14/262,845 filed Apr. 28, 2014, which is a continuation of U.S. application Ser. No. 11/879,357 filed Jul. 17, 2007, granted Apr. 29, 2014 under U.S. Pat. No. 8,709,023, which is a continuation-in-part of International PCT Application No. PCT/US2006/014939, filed Apr. 20, 2006, which claims the benefit of U.S. Provisional Application No. U.S. 60/674,826, filed Apr. 26, 2005.
This invention relates to composite warp knitted and braided constructs, each comprising two types of yarns having significantly different absorption/biodegradation and strength retention profiles to produce warp-knitted meshes and braided sutures exhibiting bimodular changes in their properties when used as surgical implants.
Blending of non-absorbable fibers having distinctly different individual physicochemical properties is a well-established practice in the textile industry and is directed toward achieving unique properties based on the constituent fibers in such blends. The most commonly acknowledged examples of these blends include combinations of (1) wool staple yarn and polyethylene terephthalate (PET) continuous multifilament yarn to produce textile fabrics which benefit from the insulating quality of wool and high tensile strength of the polyester; (2) cotton staple yarn and PET continuous multifilament yarn to produce water-absorbing, comfortable (due to cotton), strong (due to PET) fabrics; (3) nylon continuous multifilament yarn and cotton staple yarn to achieve strength and hydrophilicity; and (4) cotton staple yarn and polyurethane continuous monofilament yarn to yield water-absorbing, comfortable elastic fabrics. The concept of blending non-absorbable and absorbable fibers was addressed to a very limited extent in the prior art relative to combining polypropylene (PP) with an absorbable polyester fiber in a few fibrous constructs, such as hernial meshes, to permit tissue ingrowth in the PP component of these meshes and reducing long-term implant mass, as the absorbable fibers lose mass with time. However, the use of totally absorbable/biodegradable blends of two or more yarns to yield fibrous properties that combine those of the constituent yarns is heretofore unknown in the prior art. This provided the incentive to pursue this invention, which deals with totally absorbable/biodegradable composite yarns having at least two fibrous components and their conversion to medical devices, such as sutures and meshes, with modulated, integrated physicochemical and biological properties derived from the constituent yarns and which can be further modified to exhibit specific clinically desired properties.
A key feature of having an absorbable/biodegradable surgical implant comprising at least two differing fibrous components, which, in turn exhibit different absorption and strength retention profiles has been disclosed in the present parent application PCT Serial No. 2006014939. However, these applications did not describe any specifically new construct design of devices such as surgical sutures and hernial meshes, which are responsible for achieving novel clinical properties. Accordingly, this invention is directed to novel construct designs made of fully absorbable/biodegradable surgical sutures, especially those used in slow-healing tissues and surgical meshes such as those used in hernial repair and vaginal tissue reconstruction.
Generally, the present invention is directed to warp knitted composite meshes and braided composite sutures comprising slow-absorbable/biodegradable and fast-absorbable/biodegradable components, specially sized and constructed to produce surgical devices having unique properties.
One major aspect of this invention is directed to a warp-knitted composite mesh with a minimum area density of 50 g/m2, which includes (a) a slow absorbing/biodegradable multifilament yarn component having individual filament diameter of less than 20 micron; and (b) a fast-absorbing multifilament yarn component having individual filament diameter exceeding 20 micron, wherein the slow-absorbing/biodegradable multifilament component is a segmented copolymer made of molecular chains comprising at least 80 percent of l-lactide-based sequences and the fast-absorbing multifilament component is a segmented polyaxial copolymer made of molecular chains comprising at least 70 percent of glycolide-derived sequences, and wherein the slow-absorbing multifilament component is knitted in a 2-bar sand-fly net pattern and the fast-absorbing multifilament component is knitted in a standard 2-bar marquisette pattern, with all guide bars threaded 1-in and 1-out, using a warp knitting machine. Alternatively, the slow-absorbing multifilament component is knitted in 2-bar full tricot pattern and the fast-absorbing multifilament component yarn is knitted in a standard 2-bar marquisette pattern with all guide bars threaded 1-in and 1-out, using a warp knitting machine.
A clinically important aspect of this invention is the provision of a composite mesh having an area weight of about 130 g/m2 and exhibiting a maximum burst force of at least 250 N and a maximum elongation of less than 10 percent under a 16 N force per cm of mesh width, and when incubated in buffered solution at pH 7.2 and 50° C. for about 2 weeks retains more than 20 percent of its maximum burst force and undergoes at least 12 percent elongation under a force of 16 N per cm of mesh width.
Alternatively, the slow-absorbing/biodegradable multifilament yarn component of the mesh comprises a poly-3-hydroxyalkanoate made of molecular chains consisting of at least 50 percent of 3-hydroxybutyric acid-derived sequences.
This invention also deals with a warp-knitted composite mesh with a minimum area density of 50 g/m2, comprising (a) a slow absorbing/biodegradable multifilament yarn component having individual filament diameter of less than 20 micron; and (b) a fast-absorbing multifilament yarn component having individual filament diameter exceeding 20 micron, wherein said mesh is coated with an absorbable polymer at a coating add-on of at least 0.1 percent based on the uncoated mesh weight. Optionally, the coating comprises a polyaxial copolyester made of molecular chains comprising about 95/5ε-caprolactone-/glycolide-derived sequences, wherein the coating contains at least 1 bioactive agent selected from those groups known for their antineoplastic, anti-inflammatory, antimicrobial, anesthetic and cell growth-promoting activities.
Another major aspect of this invention deals with a braided composite suture comprising (a) a slow-absorbing/biodegradable multifilament yarn component having individual filament diameter of less than 20 micron, and capable of retaining at least 20 percent of its initial breaking strength when tested individually as a braid and incubated in a phosphate buffer at pH 7.2 and 50° C. for about 2 weeks; and (b) a fast-absorbing/biodegradable multifilament yarn component capable of retaining at least 20 percent of its initial breaking strength when tested individually as a braid and incubated in a phosphate buffer at pH 7.2 and 50° C. for about 1 day. In one embodiment the slow-absorbing/biodegradable and fast-absorbing/biodegradable multifilament components constitute the core and sheath of the braid, respectively. Alternatively, the slow-absorbing/biodegradable and fast-absorbing/biodegradable multifilament components constitute the sheath and core of the braid, respectively.
In terms of the chemical composition of the composite suture, in one embodiment the slow-absorbing/biodegradable multifilament component comprises a segmented copolymer made of the molecular chains consisting of at least 80 percent of l-lactide-derived sequences and the fast-absorbing/biodegradable multifilament component comprises a segmented polyaxial copolymer made of molecular chains consisting of at least 70 percent of glycolide-derived sequences. Alternatively, the slow absorbable/biodegradable multifilament component comprises silk, or a poly-3-hydroxyalkanoate made of a molecular chain consisting of at least 50 percent of 3-hydroxybutyric acid-derived sequences.
Additional aspects of this invention deal with a braided composite suture as described above coated with an absorbable polymer at a coating add-on of at least 0.1 percent based on the uncoated suture weight. Optionally, the coating comprises a polyaxial copolyester made of molecular chains comprising about 95/5ε-caprolactone-/glycolide-derived sequences, wherein the coating contains at least one bioactive agent selected from those groups known for their antineoplastic, anti-inflammatory, antimicrobial, anesthetic and cell growth-promoting activities.
During the first one to two days of introducing an implant in living tissue, an acute inflammation prevails at the implant site. This is manifested as redness, heat, swelling and pain. After about day three, any persistent local inflammatory response to the implant subsides. When a non-absorbable material is implanted, the acute inflammation persists for less than a week and the development of a fibrous connective tissue around the implant progresses for about a month, leading to a generally static, fibrous capsule. A long-term separation of the non-absorbable implant from surrounding tissues by the capsule can lead to complications. Depending on the type of implant site, these complications may (1) increase the risk of infection and (2) interfere with the integration of the implant components with surrounding tissue leading to mechanical instability, as in the case of hernial meshes. On the other hand, if the implant material biodegrades/absorbs over time, the inflammation can be restimulated, incrementally, during the implant residence time period at the site, a feature which can be most desirable in certain applications. These include surgical meshes used in hernial repair, where an incremental restimulation of inflammation can result in controlled and persistent collagen deposition and mechanical integration with the fibrous components of the mesh leading to critically needed mechanical stability. Obviously, one should not expect this to terminate after the first three or four weeks following implantation leading to catastrophic mechanical failure of the mesh. Additionally, the incremental restimulation of inflammation and controlled collagen deposition can be achieved through (1) movement of the mesh components and/or at the mesh-tissue interface; (2) providing continually increased porosity in the mesh to permit progressively increasing facile fibroblast migration; and (3) having structurally stable mesh construction that resists tear and unraveling under dynamic mechanical stresses. And, optimally, the mesh components should be designed to (1) exhibit at least two absorption/strength retention profiles, one that prevails during the first two to four weeks and a second which will be responsible for continued restimulation beyond four weeks; (2) display sufficient mechanical strength and stiffness in the first three to four weeks during which collagen is deposited and the mechanical load at the site commences to be shared between the mesh and surrounding tissue without experiencing premature deformation; (3) accommodate the biomechanical events associated with wound healing and tissue shrinkage, as well as incremental dynamic stresses due to regular motions of active patients, through an incremental increase in the engineering compliance of the mesh; and (4) have a carefully warp-knitted construction that accommodates mechanical changes at the implant site while resisting tearing and breaking/unraveling at the tissue-mesh interface and/or within the mesh construct itself.
In concert with the aforementioned discussion, the present invention addresses the requirements set forth for an optimal mesh. Similarly, it addresses the requirements of an optimum suture that is expected to provide an effective ligation for three to four weeks as well as up to a few months following implantation, as would be required for wound repairs of compromised and slow-healing tissues.
A key general aspect of this invention is directed to a warp-knitted composite mesh with minimum density of 50 g/m2 to ensure having adequate mass and strength to allow anchoring to the natural tissue, using a suture and/or absorbable adhesive, without tearing, unraveling, and/or breaking immediately after placement and during the first few weeks of functional performance. This is to prevent mechanical failure at the tissue-mesh interface or within the mesh components. For anchoring the mesh to the biological site, an absorbable suture of choice will be expected to maintain a strength retention profile that parallels that of a long-lasting component of the composite mesh. Meanwhile, the composite mesh is expected to comprise (1) a slow-absorbing/biodegradable, multifilament yarn component having individual filament diameter of less than 20 micron and preferably less than 15 micron as the main, relatively more flexible matrix of the mesh, which retains a measurable breaking strength for at least six weeks and preferably for more than eight weeks; (2) a fast-absorbing/biodegradable, multifilament yarn component having individual filament diameter of more than 20 micron and preferably exceeding 25 micron, as the minor, relatively less flexible component of the mesh that will be responsible for providing adequate initial rigidity of the mesh, and facile anchoring to the surrounding tissues, while exhibiting a brief breaking strength profile of about two to four weeks—this is to allow the slow-absorbing flexible matrix to become progressively more extensible at about two to four weeks following implantation; and (3) a slow- and fast-absorbing multifilament components in specially designed warp-knitted construction to ensure their mechanical interdependence in terms of load-bearing contributions and ability to anchor to the surrounding tissue using an absorbable tissue adhesive, absorbable suture, or a combination, for example, of an absorbable cyanoacrylate-based adhesive and an absorbable suture—a useful illustration of such warp-knit construction entails knitting the slow-absorbing multifilament component in a 2-bar, sand-fly net pattern and the fast-absorbing component in a standard 2-bar marquisette pattern, with all guide bars threaded 1-in and 1-out in 18 gauge using preferably a Raschel or tricot knitting machine. An alternative composite mesh construction entails knitting the slow-absorbing component using a 2-bar full tricot pattern and the fast-absorbing component using a standard 2-bar marquisette pattern, with all guide bars threaded 1-in and 1-out in 18 gauge. The warp construction can be achieved using other patterns. To improve the initial burst strength of the composite mesh through minimizing the fiber-to-fiber friction coefficient and hence minimize the fraying of the mesh structure, a lubricant coating is applied to the mesh at a level of 0.1 to 10 percent based on the mesh uncoated weight. The absorbable coating can also be used as a carrier for the controlled release of one or more bioactive agents belonging to one or more group of drugs known for their antimicrobial, anti-adhesion, and growth-promoting agents. The ideal coating system can be a crystalline, easy-to-apply, lubricious polymeric system that provides surface lubricity and its composition can be controlled to assist in modulating the absorption/biodegradation profile of the fast-absorbing component at least in the first two weeks following implantation.
Although slow- and fast-absorbable/biodegradable components of the composite are, so far, described as multifilament yarns, which are warped independently, other alternative approaches can be used entailing (1) plying the fast- with the slow-absorbable/biodegradable yarns prior to warping; (2) using one or more additional yarns with a moderate or fast absorption/biodegradation profile; (3) using the fast-absorbing component as a single or two-ply monofilament; (4) using a yarn component based on an elastomeric polymer—this can be in the form of a fast-, moderate- or faster-absorbing monofilament, 2-ply monofilament or multifilament. The use of elastomeric components is expected to accommodate any transient change in stress at the application site at the initial period of implantation when inflammation-induced swelling is encountered. To further modulate the performance of the composite mesh, enzymatically biodegradable, multifilament yarn can be used as the slow-biodegrading component. Such yarns include those based on silk fibroin, poly-4-hydroxyalkanoate, casein, chitosan, soy protein, and similar naturally derived materials with or without chemical modification to modulate their biodegradation and breaking strength retention profiles.
Another key general aspect of this invention is directed to a braided suture comprising at least two absorbable/biodegradable monofilament and/or multifilament yarn components having a range of absorption/biodegradation and breaking strength retention profiles. The rationale for invoking such a diversity in the components constituting the composite braid is practically similar to that noted above for composite mesh, with the exception of the fact that in constructing the braid, there is an additional degree of freedom, namely, having a core and sheath as the basic structural components of the braid. Meanwhile, the braid construction may entail (1) using variable ratios of the core-to-sheath without encountering core popping; (2) having slow-absorbable/biodegradable, multifilament yarn as the core or sheath with the balance of braid consisting of a fast-absorbable/biodegradable multifilament yarn; (3) using elastomeric monofilament, plied monofilament or multifilament yarn as part of the braid construct and preferably in the core at variable levels to impart a controlled level of elasticity—this is to accommodate site swelling during the first few days following suture implantation. The composite suture can be coated to (1) improve its tie-down and handling properties; (2) possibly prolong the breaking strength retention profile; and (3) function as an absorbable carrier for the controlled release of one or more bioagent selected from the groups known for their antimicrobial, anti-adhesion, antithrombogenic, antiproliferative, antineoplastic, anti-inflammatory, and cell growth-promoting activities. The coating can also be used to allow the controlled and timely delivery of anesthetic agents to mediate pains following surgery. A useful feature of using a coating with an antineoplastic agent allows the use of the composite suture in cancer patients to minimize the likelihood of metastasis. Another useful feature is the use of the composite suture in anchoring synthetic vascular graft and perivascular wrap where (1) having two or more absorption/biodegradation profiles can allow accommodating physicomechanical changes at the suture line due to prevailing biological events; and (2) using antithrombogenic and/or antiproliferative agents can be beneficial in maintaining the long-term patency of the graft.
A clinically important aspect of this invention deals with bioactive meshes comprising a coating containing an antineoplastic, anti-inflammatory, and/or antiproliferative agent that allows the use of the composite mesh as vascular wrap in the management of vascular embolism.
Further illustrations of the present invention are provided by the following examples:
A segmented l-lactide copolymer (P1) prepared by the copolymerization of a mixture of an 88/12 (molar) l-lactide/trimethylene carbonate [following the general polymerization methods described in U.S. Pat. No. 6,342,065 (2002)] was melt-spun using a 20-hole die to produce multifilament Yarn I—this is used as the slow-absorbable/biodegradable component of certain composite meshes. The extruded multifilament yarn was further oriented using a one-stage drawing over a heated Godet at about 100-120° C. prior to its use for knitted mesh construction. Typical properties of Yarn I are shown below. For producing Yarn II, the fast-absorbing/biodegradable component of the composite mesh, a polyaxial, segmented glycolide copolymer (P2), made by ring-opening polymerization of a combination of an 88/7/5 (weight) glycolide/trimethylene carbonate/l-lactide [using the general polymerization method described in U.S. Pat. No. 7,129,319 (2006)] was melt-spun using a 10-hole die and oriented by in-line drawing. Typical properties of Yarn II and the form used in knitting are shown below.
Key Properties of Yarns I and II:
Yarn I (2-Ply Natural Yarn)
-
- Fiber Count: 43
- Denier Range: 80-100 g/9000 m
- Tenacity Range: 1.8 to 4.5 g/denier
- Ultimate Elongation: 20-30%
Yarn II (1-Ply Natural Yarn)
-
- Fiber Count: 10
- Denier Range: 120-170 g/9000 m
- Tenacity Range: 3.5-5.5 g/denier
- Ultimate Elongation: 40-70%
Compositions consisting of Yarns I and II which possess different degradation profiles (one relatively fast degrading and one slow degrading) were constructed using various knitting patterns to construct the desired warp-knitted meshes. Knit constructions were produced using a two-step process of warping yarn onto beams and constructing meshes using a typical Raschel or tricot knitting machine. Various knitting patterns and weight ratios of I to II can and were varied to modulate mechanical properties of the specific mesh. Knit constructions can be made from multifilament yarn, monofilament yarn, or combinations thereof. Knit mesh was heat set or annealed at 120° C. for 1 hour while under constant strain in the wale and course directions. Coating can be applied following annealing to modify the in vivo and/or in vitro characteristics.
The knitting process utilized two warped beams of Yarn I, threaded on bars 1 and 2, and two warped beams of Yarn II threaded on bars 3 and 4. The knitting machine was equipped with 18-gauge needles. Yarn II was knitted in a 2-bar marquisette pattern and Yarn I was knitted in a 2-bar sand-fly net pattern with all guide bars for each pattern threaded 1-in and 1-out in 18 gauge.
Pattern a (28 Courses Per Inch)
Bar 1—1-0/1-2/2-3/2-1//2x (1-in, 1-out)
Bar 2—2-3/2-1/1-0/1-2//2x (1-in, 1-out)
Bar 3—1-0/0-1//4x (1-in, 1-out)
Bar 4—0-0/3-3//4x (1-in, 1-out)
The knitting process utilized two warped beams of Yarn I threaded on bars 1 and 2 and two warped beams of Yarn II, threaded on bars 3 and 4. The knitting machine was equipped with 18-gauge needles. Yarn II was knitted in a 2-bar marquisette pattern and Yarn I was knitted in a 2-bar full tricot pattern with all guide bars for each pattern threaded 1-in and 1-out in 18 gauge.
Pattern B (19 Courses Per Inch)
Bar 1—1-0/2-3//4x (1-in, 1-out)
Bar 2—2-3/1-0//4x (1-in, 1-out)
Bar 3—1-0/0-1//4x (1-in, 1-out)
Bar 4—0-0/3-3//4x (1-in, 1-out)
Testing Methods for Meshes from Example 3
Mechanical properties were characterized using the ball burst testing apparatus with physical characteristics based on the ASTM D3787-01 guideline for the fixture geometry (25.4 mm polished steel ball, 44.45 mm diameter inside opening). The mesh was clamped in the fixture without any applied tension and the ball was positioned in the center of the 44.45 mm diameter opening. The ball is then brought down to a position on the mesh such that a 0.1 N force is applied. The test is initiated and the ball travels at 2.54 cm/min until failure characterized by the point of maximum load. For each test the following three characteristics were recorded with standard deviation values for n=4 sample sizes:
- 1) Maximum burst force obtained during the test (N)
- 2) The extension at the maximum load (mm)
- 3) The extension at 71 N load (mm)
The extension at 71 N is used to determine the 16 N/cm elongation. The value of 71 N is derived from the diameter of the opening (4.445 cm×16 N/cm=71 N). Initially the mesh has a 44.45 mm diameter and is all in one plane. As the test progresses the ball pushes the mesh downward and creates a cone like shape with the radius of the ball as the tip. Using CAD and curve fitting software a mathematical expression which relates the linear travel of the ball to the change in length of a line that passes under the center of the ball and up to the original 44.45 mm diameter (radial distension) was developed. From this information the percent elongation was determined
In vitro conditioned burst strength retention [BSR=(max. load at time point/initial max. load)*100] was conducted using a MTS MiniBionix Universal Tester (model 858) equipped with a burst test apparatus as detailed in ASTM D3787-01. Samples were tested initially, after in vitro conditioning using a 0.1 M solution of buffered sodium phosphate at a 12.0 pH in 50 mL tubes for 10 days, and after conditioning using a 0.1 M solution of buffered sodium phosphate at a 7.2 pH in 50 mL tubes for multiple time points of interest. Tubes were placed in racks and incubated at 50° C. under constant orbital-agitation. Samples were removed at predetermined time points for mechanical properties testing (n=3).
Physical Properties of a Typical Warp-Knit Composite Mesh from Example 3
TABLE I |
Pattern A Warp Knit Composite Mesh Physical Properties |
Knitting | Area Weight | Yarn II Content | ||
Pattern | (g/m2) | (weight %) | ||
Pattern A | 132 | 40 | ||
Mechanical Properties of Meshes from Example 3
TABLE II |
Pattern-A Warp Knit Composite Mesh Initial Burst Properties |
Elongation | Elongation | |||
Sample | Max. Burst | at Max | at 71 N | Elongation at |
Description | Force (N) | Force (mm) | Force (mm) | 16 N/cm (%) |
Pattern A | 356 | 14.6 | 6.8 | 5.2 |
TABLE III |
Properties of Pattern A Warp Knit Composite Mesh Following |
Accelerated In Vitro Conditioning (12 pH, 50° C., 10 days) |
Elongation | Elongation | |||
Sample | Max. Burst | at Max | at 71 N | Elongation at |
Description | Force (N) | Force (mm) | Force (mm) | 16 N/cm (%) |
Pattern A | 194 | 21.5 | 15.8 | 25.6 |
TABLE IV |
Properties of Pattern A Warp Knit Composite Mesh Due to Accelerated |
In Vitro Aging (7.2 pH, 50° C.) |
Max. | |||||
Burst | Elongation at | Elongation at | Elongation at | ||
In Vitro | BSR | Force | Max Force | 71 N Force | 16 N/cm Force |
Duration | (%) | (N) | (mm) | (mm) | (%) |
0 days | — | 352 | 14.29 | 6.52 | 4.76 |
3 days | 106.3 | 374 | 14.71 | 6.84 | 5.28 |
7 days | 44.9 | 158 | 14.24 | 7.92 | 7.14 |
11 days | 59.1 | 208 | 18.89 | 13.13 | 18.38 |
14 days | 55.7 | 196 | 19.63 | 14.31 | 21.46 |
18 days | 52.6 | 185 | 17.98 | 13.20 | 18.56 |
21 days | 55.4 | 195 | 18.44 | 13.21 | 18.59 |
35 days | 51.4 | 181 | 17.88 | 13.54 | 19.43 |
56 days | 36.9 | 130 | 16.37 | 14.01 | 20.66 |
Testing Methods for Meshes from Example 4
Mechanical properties testing was conducted using a MTS MiniBionix Universal Tester (model 858) equipped with a burst test apparatus as detailed in ASTM Q3787-01. Samples were tested initially and after being conditioned using a 0.1 M solution of buffered sodium phosphate at a 12.0 pH in 50 mL tubes for 10 days. Tubes were placed in racks and incubated at 50° C. under constant orbital-agitation. Samples were removed at predetermined time points for mechanical properties testing (n=3).
Physical Properties of a Typical Warp-Knit Composite Mesh from Example 4
TABLE V |
Pattern B Warp Knit Composite Mesh Tabulated |
Physical Properties |
Knitting | Yarn B Content | |||
Pattern | Area Weight (g/m2) | (weight %) | ||
Pattern B | 135 | 31 | ||
Mesh Resultant Mechanical Properties from Example 4
TABLE VI |
Pattern B Warp Knit Composite Mesh Initial Burst Properties |
Elongation | Elongation | |||
Sample | Max. Burst | at Max | at 71 N | Elongation at |
Description | Force (N) | Force (mm) | Force (mm) | 16 N/cm (%) |
Pattern B | 436 | 16.3 | 7.1 | 5.7 |
TABLE VII |
Properties of Pattern B Warp Knit Composite Mesh Following |
Accelerated In Vitro Conditioning (12 pH, 50° C., 10 days) |
Elongation | Elongation | |||
Sample | Max. Burst | at Max | at 71 N | Elongation at |
Description | Force (N) | Force (mm) | Force (mm) | 16 N/cm (%) |
Pattern B | 240 | 19.4 | 13.2 | 18.5 |
The same polymer precursor, P2, described in Example 1 was used in preparing multifilament Yarn III. The polymer was melt-spun using a 20-hole die to produce multifilament Yarn III, which was further oriented using one-stage drawing over a heated Godet at about 100-120° C., prior to its use in braid construction.
Braid SM1-1 was prepared using a 4-carrier core of Yarn I as single ply and 8-carrier Yarn III as 3-ply. The braid was hot-stretched to about 5-10 percent of its initial length using heated air at about 90° C. to tighten the braid construction. The strained braid was then annealed at 110° C. for 1 hour to yield a braided suture having about 110 ppi and a diameter of about 0.35 mm.
Braid SM1-2 was prepared using a 6-carrier core of Yarn III as single ply and 16-carrier sheath of Yarn I as single ply. The braid was hot stretched and annealed as described in Example 8 to yield a braided suture having about 50 ppi and a diameter of about 0.36.
The braids were sterilized with ethylene oxides and tested for their (1) initial physical properties; (2) accelerated in vitro breaking strength retention profile at pH 7.2 and 50° C.; and (3) in vivo breaking strength retention using a subcutaneous rat model. The results of the in vitro and in vivo evaluation are summarized in Table VIII.
TABLE VIII |
In Vitro and In Vivo Properties of Composite Braids SMI-1 and SMI-2 |
Experiment | Braid SMI-1 | Braid SMI-2 |
Physical Properties: | ||
Diameter, mm | 0.35 | 0.36 |
Initial Strength, Kpsi (N) | 54.4 (36.1) | 52.4 (36.7) |
Elongation, % | 45 | 41 |
Knot Max. Load, N | 24.7 | 23.7 |
In vitro Breaking Strength Retention (BSR) | ||
at pH 7.2/50° C. Percent at | ||
Days 1, 2, and 3 | 85, 50, 24 | 81, 80, — |
Weeks 1 and 2 | 21, 19 | 76, 76 |
In-Vivo BSR at Percent at Weeks 2 and 3 | 43, 25 | 81, 77 |
Preferred embodiments of the invention have been described using specific terms and devices. The words and terms used are for illustrative purposes only. The words and terms are words and terms of description, rather than of limitation. It is to be understood that changes and variations may be made by those of ordinary skill art without departing from the spirit or scope of the invention, which is set forth in the following claims. In addition it should be understood that aspects of the various embodiments may be interchanged in whole or in part. Therefore, the spirit and scope of the appended claims should not be limited to descriptions and examples herein.
Claims (6)
1. A biodegradable knitted mesh comprising: at least first and second yarn components, the yarn components having differing absorption profiles and differing strength retention profiles in the biological environment; wherein the first yarn component further comprises a monofilament of a slow absorbing copolyester; the second yarn component comprises a monofilament of a fast absorbing copolyester; the first yarn component comprising a segmented polymer comprising at least 80 percent of l-lactide-based sequences; the second yarn component comprising a segmented copolymer comprising at least 70 percent of glycolide-based sequences;
wherein the biodegradable knitted mesh is knit in a four bar pattern wherein the slow-absorbing first yarn component is knit in a two bar pattern and the fast-absorbing second yarn component is knit in a two bar pattern and are initially mechanically interdependent, and
wherein upon incubation in a buffered solution at a pH of 7.2 at about 50° C. for about 2 weeks the biodegradable knitted mesh retains more than 20 percent of its maximum burst force and undergoes at least 12 percent elongation under a force of 16 N per cm of mesh width.
2. The biodegradable knitted mesh of claim 1 , wherein the second yarn component is a segmented polyaxial copolymer.
3. The biodegradable knitted mesh of claim 1 , wherein either the first yarn component or the second yarn component is an elastomeric monofilament.
4. The biodegradable knitted mesh of claim 1 , wherein both the first yarn component and the second yarn component are an elastomeric monofilament.
5. The biodegradable knitted mesh of claim 1 , wherein the biodegradable knitted mesh includes a bioactive agent selected from the group consisting of antimicrobial agents, analgesic agents, antineoplastic agents, anti-inflammatory agents, cell growth promoters, and combinations thereof.
6. The biodegradable knitted mesh of claim 1 , wherein the biodegradable knitted mesh comprises a knitted mesh construct for use in hernial repair.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/795,922 US10085826B2 (en) | 2005-04-26 | 2015-07-10 | Absorbable/biodegradable composite yarn constructs and applications thereof |
US16/129,293 US10856960B2 (en) | 2005-04-26 | 2018-09-12 | Absorbable/biodegradable composite yarn constructs and applications thereof |
US17/088,706 US20210128288A1 (en) | 2005-04-26 | 2020-11-04 | Absorbable/biodegradable composite yarn constructs and applications thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67482605P | 2005-04-26 | 2005-04-26 | |
PCT/US2006/014939 WO2006116000A2 (en) | 2005-04-26 | 2006-04-20 | Absorbable/biodegradable composite yarns and property-modulated surgical implants therefrom |
US11/879,357 US8709023B2 (en) | 2007-07-17 | 2007-07-17 | Absorbable / biodegradable composite yarn constructs and applications thereof |
US14/262,845 US10098722B2 (en) | 2005-04-26 | 2014-04-28 | Absorbable/biodegradable composite yarn constructs and applications thereof |
US14/795,922 US10085826B2 (en) | 2005-04-26 | 2015-07-10 | Absorbable/biodegradable composite yarn constructs and applications thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/262,845 Continuation US10098722B2 (en) | 2005-04-26 | 2014-04-28 | Absorbable/biodegradable composite yarn constructs and applications thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/129,293 Continuation US10856960B2 (en) | 2005-04-26 | 2018-09-12 | Absorbable/biodegradable composite yarn constructs and applications thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20150305848A1 US20150305848A1 (en) | 2015-10-29 |
US10085826B2 true US10085826B2 (en) | 2018-10-02 |
Family
ID=39967986
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/879,357 Active 2037-06-23 US8709023B2 (en) | 2005-04-26 | 2007-07-17 | Absorbable / biodegradable composite yarn constructs and applications thereof |
US14/262,845 Active 2035-01-21 US10098722B2 (en) | 2005-04-26 | 2014-04-28 | Absorbable/biodegradable composite yarn constructs and applications thereof |
US14/795,922 Active 2027-05-24 US10085826B2 (en) | 2005-04-26 | 2015-07-10 | Absorbable/biodegradable composite yarn constructs and applications thereof |
US16/129,293 Active 2026-08-15 US10856960B2 (en) | 2005-04-26 | 2018-09-12 | Absorbable/biodegradable composite yarn constructs and applications thereof |
US17/088,706 Pending US20210128288A1 (en) | 2005-04-26 | 2020-11-04 | Absorbable/biodegradable composite yarn constructs and applications thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/879,357 Active 2037-06-23 US8709023B2 (en) | 2005-04-26 | 2007-07-17 | Absorbable / biodegradable composite yarn constructs and applications thereof |
US14/262,845 Active 2035-01-21 US10098722B2 (en) | 2005-04-26 | 2014-04-28 | Absorbable/biodegradable composite yarn constructs and applications thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/129,293 Active 2026-08-15 US10856960B2 (en) | 2005-04-26 | 2018-09-12 | Absorbable/biodegradable composite yarn constructs and applications thereof |
US17/088,706 Pending US20210128288A1 (en) | 2005-04-26 | 2020-11-04 | Absorbable/biodegradable composite yarn constructs and applications thereof |
Country Status (4)
Country | Link |
---|---|
US (5) | US8709023B2 (en) |
EP (1) | EP2016956B1 (en) |
JP (1) | JP5336061B2 (en) |
CN (1) | CN101348972B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190083222A1 (en) * | 2005-04-26 | 2019-03-21 | Poly-Med, Inc. | Absorbable / biodegradable composite yarn constructs and applications thereof |
US11554007B2 (en) | 2018-02-20 | 2023-01-17 | Tepha, Inc. | Expandable absorbable implants for breast reconstruction and augmentation |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6902932B2 (en) * | 2001-11-16 | 2005-06-07 | Tissue Regeneration, Inc. | Helically organized silk fibroin fiber bundles for matrices in tissue engineering |
US9566370B2 (en) | 2004-12-23 | 2017-02-14 | Novus Scientific Ab | Mesh implant for use in reconstruction of soft tissue defects |
US9717825B2 (en) | 2004-12-23 | 2017-08-01 | Novus Scientific Ab | Mesh implant for use in reconstruction of soft tissue defects |
KR101354527B1 (en) | 2005-05-04 | 2014-01-21 | 진테스 게엠베하 | Joining element |
US8076388B2 (en) * | 2005-11-28 | 2011-12-13 | Poly-Med, Inc. | Self-setting polymeric cyanoacrylate composites |
US8083755B2 (en) | 2006-06-22 | 2011-12-27 | Novus Scientific Pte. Ltd. | Mesh implant for use in reconstruction of soft tissue defects |
US9011439B2 (en) | 2006-11-20 | 2015-04-21 | Poly-Med, Inc. | Selectively absorbable/biodegradable, fibrous composite constructs and applications thereof |
US8016841B2 (en) * | 2007-06-11 | 2011-09-13 | Novus Scientific Pte. Ltd. | Mesh implant with an interlocking knitted structure |
CN105063875A (en) | 2008-12-15 | 2015-11-18 | 阿勒根公司 | Manufacturing method for knitted mesh of prosthetic device |
US9326840B2 (en) * | 2008-12-15 | 2016-05-03 | Allergan, Inc. | Prosthetic device and method of manufacturing the same |
US9204954B2 (en) * | 2008-12-15 | 2015-12-08 | Allergan, Inc. | Knitted scaffold with diagonal yarn |
US9308070B2 (en) * | 2008-12-15 | 2016-04-12 | Allergan, Inc. | Pliable silk medical device |
US9204953B2 (en) * | 2008-12-15 | 2015-12-08 | Allergan, Inc. | Biocompatible surgical scaffold with varying stretch |
ITMI20090053A1 (en) * | 2009-01-20 | 2010-07-21 | Antonio Sambusseti | REASSEMBLABLE PATCH FOR THE REPLACEMENT OF A VESCICAL WALL PORTION FOLLOWED BY PARTIAL VESCITECTOMY |
US20110052695A1 (en) * | 2009-04-20 | 2011-03-03 | Allergan, Inc. | Drug delivery platforms comprising silk fibroin hydrogels and uses thereof |
ES2414879T4 (en) * | 2009-04-20 | 2013-10-30 | Allergan, Inc. | Silk fibroin hydrogels and their uses |
US20110111031A1 (en) * | 2009-04-20 | 2011-05-12 | Guang-Liang Jiang | Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof |
US20110189292A1 (en) * | 2009-04-20 | 2011-08-04 | Allergan, Inc. | Dermal fillers comprising silk fibroin hydrogels and uses thereof |
US20120165957A1 (en) | 2009-07-06 | 2012-06-28 | Hanne Everland | Biodegradable scaffold for soft tissue regeneration and use thereof |
EP2475330A1 (en) * | 2009-09-11 | 2012-07-18 | Allergan, Inc. | Prosthetic device and method of manufacturing the same |
US8758798B2 (en) | 2010-03-24 | 2014-06-24 | Covidien Lp | Therapeutic implant |
US8758799B2 (en) | 2010-03-24 | 2014-06-24 | Covidien Lp | Therapeutic implant |
US9757132B2 (en) | 2010-03-24 | 2017-09-12 | Biorez, Inc. | Mechanically competent scaffold for rotator cuff and tendon augmentation |
US8758800B2 (en) | 2010-03-24 | 2014-06-24 | Covidien Lp | Therapeutic implant |
KR101028248B1 (en) * | 2010-06-09 | 2011-04-11 | 주식회사 메타바이오메드 | The method of manufacturing a suture |
FR2962646B1 (en) | 2010-07-16 | 2012-06-22 | Sofradim Production | PROSTHETIC WITH RADIO OPAQUE ELEMENT |
US9861590B2 (en) | 2010-10-19 | 2018-01-09 | Covidien Lp | Self-supporting films for delivery of therapeutic agents |
FR2977790B1 (en) | 2011-07-13 | 2013-07-19 | Sofradim Production | PROSTHETIC FOR UMBILIC HERNIA |
US8579924B2 (en) | 2011-07-26 | 2013-11-12 | Covidien Lp | Implantable devices including a mesh and a pivotable film |
US9782957B2 (en) | 2011-08-24 | 2017-10-10 | Covidien Lp | Medical device films |
US8932621B2 (en) | 2011-10-25 | 2015-01-13 | Covidien Lp | Implantable film/mesh composite |
US9179994B2 (en) | 2011-10-25 | 2015-11-10 | Covidien Lp | Implantable film/mesh composite |
US9005308B2 (en) | 2011-10-25 | 2015-04-14 | Covidien Lp | Implantable film/mesh composite for passage of tissue therebetween |
US9080263B2 (en) | 2012-02-10 | 2015-07-14 | Novus Scientific Ab | Multifilaments with time-dependent characteristics, and medical products made from such multifilaments |
EP2626454B1 (en) * | 2012-02-10 | 2014-08-13 | Novus Scientific AB | Multifilaments with time-dependent characteristics and medical products made thereof |
AU2013226225A1 (en) | 2012-03-01 | 2014-10-16 | Synthes Gmbh | Surgical suture with soft core |
US10206769B2 (en) | 2012-03-30 | 2019-02-19 | Covidien Lp | Implantable devices including a film providing folding characteristics |
US11959207B2 (en) | 2012-04-06 | 2024-04-16 | Poly-Med, Inc. | Polymeric mesh products, method of making and use thereof |
FR2992662B1 (en) | 2012-06-28 | 2014-08-08 | Sofradim Production | KNIT WITH PICOTS |
FR2992547B1 (en) | 2012-06-29 | 2015-04-24 | Sofradim Production | PROSTHETIC FOR HERNIA |
US8994176B2 (en) | 2012-12-13 | 2015-03-31 | Taiwan Semiconductor Manufacturing Company, Ltd. | Methods and apparatus for package with interposers |
US9433489B2 (en) * | 2013-03-12 | 2016-09-06 | Soft Tissue Regeneration, Inc. | Absorbable synthetic braided matrix for breast reconstruction and hernia repair |
CN105050634B (en) * | 2013-03-15 | 2018-04-10 | 波士顿科学医学有限公司 | Asurgical mesh based on multicomponent filaments |
EP3036098A1 (en) * | 2013-08-22 | 2016-06-29 | Allergan, Inc. | Implantable medical devices |
CN105056311B (en) * | 2015-08-04 | 2017-11-28 | 苏州大学 | Anal fistula line with three-dimensional composite structure and preparation method thereof |
EP3851083B1 (en) * | 2018-09-14 | 2024-06-19 | Hakujuji Kabushiki Kaisha | Medical gauze |
JP2022544470A (en) * | 2019-08-13 | 2022-10-19 | エブリウェア アパレル インコーポレイテッド | Biodegradable fiber yarn made from recycled materials and method and apparatus for its production |
KR102587534B1 (en) * | 2019-12-11 | 2023-10-11 | 주식회사 엠아이텍 | Biodegradable tube including radiographic materials |
CN114177343A (en) * | 2021-11-12 | 2022-03-15 | 长春圣博玛生物材料有限公司 | Suture, preparation method and medical braided fabric |
CN116135177A (en) * | 2023-02-23 | 2023-05-19 | 赫美康健(北京)医疗器械有限公司 | Degradable self-fixing preperitoneal patch |
Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143082A (en) | 1991-04-03 | 1992-09-01 | Ethicon, Inc. | Surgical device for enclosing an internal organ |
US5217495A (en) | 1989-05-10 | 1993-06-08 | United States Surgical Corporation | Synthetic semiabsorbable composite yarn |
US5458636A (en) | 1994-07-20 | 1995-10-17 | U.S. Biomaterials Corporation | Prosthetic device for repair and replacement of fibrous connective tissue |
WO1999051163A1 (en) | 1998-04-03 | 1999-10-14 | Bionx Implants Oy | Hernia mesh |
US6014939A (en) | 1997-01-29 | 2000-01-18 | Hydralift, Inc. | Universally stable oil well ship turret |
US6063105A (en) * | 1996-06-18 | 2000-05-16 | United States Surgical | Medical devices fabricated from elastomeric alpha-olefins |
JP2000279433A (en) | 1999-03-20 | 2000-10-10 | Aesculap Ag & Co Kg | Flat implant, its production and use in surgical operation |
US6342065B1 (en) | 1999-03-17 | 2002-01-29 | Poly-Med, Inc. | High strength fibers of L-lactide copolymers ε-caprolactone and trimethylene carbonate and absorbable medical constructs thereof |
WO2002012029A1 (en) | 2000-08-03 | 2002-02-14 | Toyota Jidosha Kabushiki Kaisha | Airbag trigger control system |
US6350284B1 (en) | 1998-09-14 | 2002-02-26 | Bionx Implants, Oy | Bioabsorbable, layered composite material for guided bone tissue regeneration |
US6391037B1 (en) * | 2000-03-02 | 2002-05-21 | Prodesco, Inc. | Bag for use in the intravascular treatment of saccular aneurysms |
US6398814B1 (en) | 1998-09-14 | 2002-06-04 | Bionx Implants Oy | Bioabsorbable two-dimensional multi-layer composite device and a method of manufacturing same |
JP2002210523A (en) | 2001-01-16 | 2002-07-30 | Amada Co Ltd | Punch press |
US20020120291A1 (en) | 1999-03-17 | 2002-08-29 | Shalaby Shalaby W. | Coated, slow-absorbing textile constructs for sutures and tissue engineering |
US6462169B1 (en) | 1999-11-30 | 2002-10-08 | Poly-Med, Inc. | Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom |
US6498229B1 (en) | 2001-09-05 | 2002-12-24 | Poly-Med, Inc. | Direct synthesis of segmented glycolide copolymers and crystalline materials therefrom |
US20030040809A1 (en) | 1999-03-20 | 2003-02-27 | Helmut Goldmann | Flat implant for use in surgery |
WO2003092758A1 (en) | 2002-05-03 | 2003-11-13 | Ethicon Gmbh | Surgical thread and surgical implant with the same |
US20040028583A1 (en) | 2001-12-07 | 2004-02-12 | Hedman David E. | Portable decontamination unit useful in destroying harmful biological agents in contaminated objects |
WO2004028583A2 (en) | 2002-09-26 | 2004-04-08 | Angiotech International Ag | Perivascular wraps |
CN1501992A (en) | 2001-03-27 | 2004-06-02 | Fibers comprising polyhydroxyalkanoate copolymer/polylactic acid polymer or copolymer blends | |
JP2004523291A (en) | 2001-02-13 | 2004-08-05 | エシコン・ゲーエムベーハー | Manufacturing method of medical implant |
WO2006116000A2 (en) | 2005-04-26 | 2006-11-02 | Poly-Med, Inc. | Absorbable/biodegradable composite yarns and property-modulated surgical implants therefrom |
US20070198040A1 (en) | 2006-02-08 | 2007-08-23 | Tyrx Pharma Inc. | Temporarily Stiffened Mesh Prostheses |
JP2007277732A (en) | 2006-04-03 | 2007-10-25 | Teijin Fibers Ltd | Method for producing rubber-reinforcing fiber |
CN101081706A (en) | 2006-12-27 | 2007-12-05 | 韩建民 | Electricity, salt and water co-production sea water desalination system |
JP2008508944A (en) | 2004-08-04 | 2008-03-27 | ノボステント コーポレイション | Vascular prosthesis with improved flexibility and nested cell delivery configuration |
US20080306494A1 (en) * | 2007-06-11 | 2008-12-11 | Radi Medical Systems Ab | Mesh implant with an interlocking knitted structure |
EP2016956A2 (en) | 2007-07-17 | 2009-01-21 | Poly-Med, Inc. | Absorbable/biodegradable composite yarn contructs and applications thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2143692A1 (en) | 1994-03-31 | 1995-10-01 | Robert M. Morena | Fusion seal, sealing materials and use in crt |
JP3331260B2 (en) | 1994-08-19 | 2002-10-07 | 日本エレクトロプレイテイング・エンジニヤース株式会社 | Electroless gold plating solution |
CN1062773C (en) * | 1998-04-16 | 2001-03-07 | 中国纺织大学 | Polyester absorbable medical suture and its manufacturing method |
CN1502992A (en) | 2002-11-26 | 2004-06-09 | 华侨大学 | Growth hormone conjunctive protein activity determination kit, preparation and determination method |
WO2005016389A2 (en) * | 2003-08-04 | 2005-02-24 | Kelly Jackson | Medical instruments and methods for using the same |
-
2007
- 2007-07-17 US US11/879,357 patent/US8709023B2/en active Active
- 2007-10-24 CN CN2007101817062A patent/CN101348972B/en active Active
- 2007-10-25 JP JP2007277732A patent/JP5336061B2/en active Active
- 2007-10-26 EP EP07020990.3A patent/EP2016956B1/en active Active
-
2014
- 2014-04-28 US US14/262,845 patent/US10098722B2/en active Active
-
2015
- 2015-07-10 US US14/795,922 patent/US10085826B2/en active Active
-
2018
- 2018-09-12 US US16/129,293 patent/US10856960B2/en active Active
-
2020
- 2020-11-04 US US17/088,706 patent/US20210128288A1/en active Pending
Patent Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217495A (en) | 1989-05-10 | 1993-06-08 | United States Surgical Corporation | Synthetic semiabsorbable composite yarn |
US5143082A (en) | 1991-04-03 | 1992-09-01 | Ethicon, Inc. | Surgical device for enclosing an internal organ |
US5458636A (en) | 1994-07-20 | 1995-10-17 | U.S. Biomaterials Corporation | Prosthetic device for repair and replacement of fibrous connective tissue |
US6063105A (en) * | 1996-06-18 | 2000-05-16 | United States Surgical | Medical devices fabricated from elastomeric alpha-olefins |
US6014939A (en) | 1997-01-29 | 2000-01-18 | Hydralift, Inc. | Universally stable oil well ship turret |
US6319264B1 (en) * | 1998-04-03 | 2001-11-20 | Bionx Implants Oy | Hernia mesh |
WO1999051163A1 (en) | 1998-04-03 | 1999-10-14 | Bionx Implants Oy | Hernia mesh |
US6398814B1 (en) | 1998-09-14 | 2002-06-04 | Bionx Implants Oy | Bioabsorbable two-dimensional multi-layer composite device and a method of manufacturing same |
US6350284B1 (en) | 1998-09-14 | 2002-02-26 | Bionx Implants, Oy | Bioabsorbable, layered composite material for guided bone tissue regeneration |
US6342065B1 (en) | 1999-03-17 | 2002-01-29 | Poly-Med, Inc. | High strength fibers of L-lactide copolymers ε-caprolactone and trimethylene carbonate and absorbable medical constructs thereof |
US20020120291A1 (en) | 1999-03-17 | 2002-08-29 | Shalaby Shalaby W. | Coated, slow-absorbing textile constructs for sutures and tissue engineering |
JP2000279433A (en) | 1999-03-20 | 2000-10-10 | Aesculap Ag & Co Kg | Flat implant, its production and use in surgical operation |
US20030040809A1 (en) | 1999-03-20 | 2003-02-27 | Helmut Goldmann | Flat implant for use in surgery |
US6462169B1 (en) | 1999-11-30 | 2002-10-08 | Poly-Med, Inc. | Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom |
US6391037B1 (en) * | 2000-03-02 | 2002-05-21 | Prodesco, Inc. | Bag for use in the intravascular treatment of saccular aneurysms |
WO2002012029A1 (en) | 2000-08-03 | 2002-02-14 | Toyota Jidosha Kabushiki Kaisha | Airbag trigger control system |
JP2002210523A (en) | 2001-01-16 | 2002-07-30 | Amada Co Ltd | Punch press |
JP2004523291A (en) | 2001-02-13 | 2004-08-05 | エシコン・ゲーエムベーハー | Manufacturing method of medical implant |
CN1501992A (en) | 2001-03-27 | 2004-06-02 | Fibers comprising polyhydroxyalkanoate copolymer/polylactic acid polymer or copolymer blends | |
US6498229B1 (en) | 2001-09-05 | 2002-12-24 | Poly-Med, Inc. | Direct synthesis of segmented glycolide copolymers and crystalline materials therefrom |
US20040028583A1 (en) | 2001-12-07 | 2004-02-12 | Hedman David E. | Portable decontamination unit useful in destroying harmful biological agents in contaminated objects |
WO2003092758A1 (en) | 2002-05-03 | 2003-11-13 | Ethicon Gmbh | Surgical thread and surgical implant with the same |
WO2004028583A2 (en) | 2002-09-26 | 2004-04-08 | Angiotech International Ag | Perivascular wraps |
JP2008508944A (en) | 2004-08-04 | 2008-03-27 | ノボステント コーポレイション | Vascular prosthesis with improved flexibility and nested cell delivery configuration |
WO2006116000A2 (en) | 2005-04-26 | 2006-11-02 | Poly-Med, Inc. | Absorbable/biodegradable composite yarns and property-modulated surgical implants therefrom |
EP1874226A2 (en) | 2005-04-26 | 2008-01-09 | Poly-Med, Inc. | Absorbable/biodegradable composite yarns and property-modulated surgical implants therefrom |
US20070198040A1 (en) | 2006-02-08 | 2007-08-23 | Tyrx Pharma Inc. | Temporarily Stiffened Mesh Prostheses |
JP2007277732A (en) | 2006-04-03 | 2007-10-25 | Teijin Fibers Ltd | Method for producing rubber-reinforcing fiber |
CN101081706A (en) | 2006-12-27 | 2007-12-05 | 韩建民 | Electricity, salt and water co-production sea water desalination system |
US20080306494A1 (en) * | 2007-06-11 | 2008-12-11 | Radi Medical Systems Ab | Mesh implant with an interlocking knitted structure |
EP2016956A2 (en) | 2007-07-17 | 2009-01-21 | Poly-Med, Inc. | Absorbable/biodegradable composite yarn contructs and applications thereof |
US8709023B2 (en) * | 2007-07-17 | 2014-04-29 | Poly-Med, Inc. | Absorbable / biodegradable composite yarn constructs and applications thereof |
Non-Patent Citations (64)
Title |
---|
(CN Pat App No. 200680013813.8) first Office Action dated Jan. 22, 2010). |
(CN Pat App No. 200680013813.8) fourth Office Action dated Sep. 6, 2011). |
(CN Pat App No. 200680013813.8) second Office Action dated Jul. 6, 2010). |
(CN Pat App No. 200680013813.8) third Office Action dated Mar. 29, 2011). |
(CN Pat App No. 2007101817062) first Office Action dated Dec. 31, 2010). |
(CN Pat App No. 2007101817062) second Office Action dated Dec. 31, 2011. |
(CN Pat App No. 201410126879.4) first Office Action dated Jul. 23, 2015. |
(CN Pat App No. 201410126879.4) second Office Action dated Jan. 15, 2016. |
(EP 07020990.3) Communication from EPO. |
(EP 1874226) Communication dated Jun. 25, 2014. |
(JP Pat App No. 2007277732) Office Action dated Mar. 12, 2013. |
(JP Pat App No. 2008-505944) first Office Action. |
(JP Pat App No. 2008-505944) second Office Action. |
(PCT/US2006/014939) International Preliminary Report on Patentability dated Nov. 13, 2007. |
(PCT/US2006/014939) Written Opinion of the International Searching Authority dated Nov. 9, 2007. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Amendment filed Feb. 24, 2014. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Amendment with Filing CPA/RCE filed Feb. 18, 2011. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Amendment/Request for Reconsideration After Non-Final Rejection filed Jun. 24, 2010. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Amendment/Request for Reconsideration-After Non-Final Rejection filed Nov. 20, 2013. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Amendment/Request for Reconsideration—After Non-Final Rejection filed Nov. 20, 2013. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Applicant's Arguments/Remarks made in an Amendment filed Jan. 4, 2010. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Applicants' Arguments/Remarks Made in an Amendment filed Nov. 20, 2013. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Final Rejection dated Aug. 19, 2010. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Issue Fee Payment (PTO-85B) filed Mar. 10, 2014. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Issue Notification issued Apr. 9, 2014. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Non-Final Rejection dated Mar. 24, 2010. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Non-Final Rejection dated May 30, 2013. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Notice of Allowance and Fees Due (PTOL-85) dated Dec. 10, 2013. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Request for Continued Examination filed Feb. 18, 2011. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Requirement for Restriction/Election dated Dec. 1, 2009. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Response to Amendment under Rule 312 dated Mar. 14, 2014. |
(U.S. Appl. No. 11/879,357) (now U.S. Pat. No. 8,709,023) Response to Restriction Requirement filed Jan. 4, 2010. |
(U.S. Appl. No. 11/885,370) (now U.S. Pat. No. 8,585,772) Amendment After Notice of Allowance under Rule 312 filed Oct. 10, 2013. |
(U.S. Appl. No. 11/885,370) (now U.S. Pat. No. 8,585,772) Amendment Submitted/Entered with Filing of CPA/RCE filed Jun. 6, 2011. |
(U.S. Appl. No. 11/885,370) (now U.S. Pat. No. 8,585,772) Amendment/Request for Reconsideration After Non-Final Rejection filed Sep. 13, 2010. |
(U.S. Appl. No. 11/885,370) (now U.S. Pat. No. 8,585,772) Final Rejection dated Dec. 6, 2010. |
(U.S. Appl. No. 11/885,370) (now U.S. Pat. No. 8,585,772) Issue Fee Payment (PTO-85B) and Fee Worksheet (SB06) filed Oct. 15, 2013. |
(U.S. Appl. No. 11/885,370) (now U.S. Pat. No. 8,585,772) Non-Final Rejection dated May 19, 2010. |
(U.S. Appl. No. 11/885,370) (now U.S. Pat. No. 8,585,772) Notice of Allowance and Fees Due (PTOL-85) dated Jul. 15, 2013. |
(U.S. Appl. No. 11/885,370) (now U.S. Pat. No. 8,585,772) Response to Amendment Under Rule 312 filed Oct. 23, 2013. |
Amendment after Non-Final Office Action dated Mar. 12, 2018 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.-inventors) (3 pages). |
Amendment after Non-Final Office Action dated Mar. 12, 2018 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.—inventors) (3 pages). |
Amendment filed after Non-Final Office Action dated Dec. 28, 2016 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.-inventors) (7 pages). |
Amendment filed after Non-Final Office Action dated Dec. 28, 2016 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.—inventors) (7 pages). |
Final Rejection dated Feb. 1, 2017 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.-inventors) (10 pages). |
Final Rejection dated Feb. 1, 2017 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.—inventors) (10 pages). |
Non-Final Office Action dated Jun. 29, 2016 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.-inventors) (13 pages). |
Non-Final Office Action dated Jun. 29, 2016 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.—inventors) (13 pages). |
Non-Final Office Action dated Oct. 11, 2017 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.-inventors) (10 pages). |
Non-Final Office Action dated Oct. 11, 2017 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.—inventors) (10 pages). |
Preliminary Amendment filed May 2, 2014 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.-inventors) (8 pages). |
Preliminary Amendment filed May 2, 2014 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.—inventors) (8 pages). |
Request for Continued Examination dated Jul. 31, 2017 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.-inventors) (10 pages). |
Request for Continued Examination dated Jul. 31, 2017 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.—inventors) (10 pages). |
Requirement for Restriction dated Apr. 28, 2016 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.-inventors) (8 pages). |
Requirement for Restriction dated Apr. 28, 2016 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.—inventors) (8 pages). |
Response to Restriction Requirement filed May 23, 2016 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.-inventors) (3 pages). |
Response to Restriction Requirement filed May 23, 2016 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.—inventors) (3 pages). |
Terminal Disclaimer issued Mar. 12, 2018 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.-inventors) (2 pages). |
Terminal Disclaimer issued Mar. 12, 2018 for U.S. Appl. No. 14/262,845, filed Apr. 28, 2014 (Shalaby, et al.—inventors) (2 pages). |
U.S. Appl. No. 11/879,357 (U.S. Pat. No. 8,709,023), filed Jul. 17, 2007 (Apr. 29, 2014), Shalaby. |
U.S. Appl. No. 11/886,370 (U.S. Pat. No. 8,585,772), filed Apr. 20, 2006 (Nov. 19, 2013), Shalaby. |
U.S. Appl. No. 14/262,845 (U.S. Pat. No. 2014/0309667), filed Jul. 17, 2007 (Oct. 16, 2014), Shalaby. |
U.S. Appl. No. 60/674,826, filed Apr. 20, 2005, Shalaby. |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190083222A1 (en) * | 2005-04-26 | 2019-03-21 | Poly-Med, Inc. | Absorbable / biodegradable composite yarn constructs and applications thereof |
US10856960B2 (en) * | 2005-04-26 | 2020-12-08 | Poly-Med, Inc. | Absorbable/biodegradable composite yarn constructs and applications thereof |
US11554007B2 (en) | 2018-02-20 | 2023-01-17 | Tepha, Inc. | Expandable absorbable implants for breast reconstruction and augmentation |
Also Published As
Publication number | Publication date |
---|---|
JP5336061B2 (en) | 2013-11-06 |
CN101348972B (en) | 2012-11-07 |
CN101348972A (en) | 2009-01-21 |
US20140309667A1 (en) | 2014-10-16 |
US20190083222A1 (en) | 2019-03-21 |
US20180296312A9 (en) | 2018-10-18 |
US10856960B2 (en) | 2020-12-08 |
EP2016956A3 (en) | 2010-11-10 |
US20150305848A1 (en) | 2015-10-29 |
EP2016956A2 (en) | 2009-01-21 |
EP2016956B1 (en) | 2019-06-19 |
US20210128288A1 (en) | 2021-05-06 |
JP2009022728A (en) | 2009-02-05 |
US10098722B2 (en) | 2018-10-16 |
US8709023B2 (en) | 2014-04-29 |
US20090024162A1 (en) | 2009-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10856960B2 (en) | Absorbable/biodegradable composite yarn constructs and applications thereof | |
US20240218575A1 (en) | Polymeric mesh products, method of making and use thereof | |
EP1874226B1 (en) | Absorbable/biodegradable composite yarns and property-modulated surgical implants therefrom | |
US9884140B2 (en) | Selectively absorbable/biodegradable fibrous composite constructs and applications thereof | |
US10314683B2 (en) | Polyhydroxyalkanoate medical textiles and fibers | |
EP0485986A1 (en) | Connective tissue prosthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: POLY-MED, INC., SOUTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHALABY, SHALABY W;PENISTON, SHAWN J;TAYLOR, MICHAEL S;AND OTHERS;SIGNING DATES FROM 20070815 TO 20070816;REEL/FRAME:054267/0835 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |